TSHA Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Taysha Gene Therapies | Updated today | Last updated: 2026-07-27

TickerTSHA

Market Capn/a

Cash RunwayUnknown

Next Catalyst2027-03-12

Public Research Snapshot

Taysha Gene Therapies is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for TSHA-102 in Rett Syndrome (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
TSHA-102	Rett Syndrome	n/a	Phase 3	Public pipeline row
None (Observational study)	Leigh Syndrome	n/a	n/a	Public pipeline row
TSHA-101	Infantile GM2 Gangliosidosis (Disorder)	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-03-12	TSHA-101	Low
		Clinical Trial Completion	2031-06	TSHA-102	Low

Cash Runway Preview

Estimated cash runway: Unknown.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05277363	n/a	WITHDRAWN	n/a	2022-05-04
NCT04798235	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	3	2027-03-12
NCT06152237	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	6	2028-11-02
NCT07480564	Phase 3	RECRUITING	3	2031-06
NCT05606614	Phase 3	RECRUITING	15	2031-06

Scientific Context

asset_name | None (Observational study)
indication | Leigh Syndrome
indication | Leigh Syndrome
asset_name | TSHA-101
catalyst_date_estimated | 2027-03-12

Want the full TSHA research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.